ClinicalTrials.gg
CompletedNCT04810741RETROBIZHUpdated Jan 13, 2023

Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France

An observational study in Schistosomiasis, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
532
Ages
18 Years and older
Sex
All
01

Study summary

Schistosomiasis is a major public health issue. Clinical guidelines for the management of imported schistosomiasis are heterogeneous. The objective of this study is to describe the clinical management of schistosomiasis imported cases in France, regarding diagnosis, treatment and follow-up.

Read the detailed description

Schistosomiasis is a major public health issue. Clinical guidelines for the management of imported schistosomiasis are heterogeneous. The objective of this study is to describe the clinical management of schistosomiasis imported cases in France, regarding diagnosis, treatment and follow-up. It is a multicentric, retrospective, descriptive study. Inclusion criteria are an age ≥ 18, a positive western blot and / or a positive microscopy exam. Data concerning clinical presentation, biological samples, imaging, treatment and follow-up will be assessed. A descriptive analysis will be performed.

02

Conditions studied

  • Schistosomiasis

Browse trials for

Keywords

  • schistosomiasis, retrospective
03

In context

Schistosomiasis

79 studies on the registry are indexed under Schistosomiasis; 14 are open to participants now.

This study's enrollment of 532 is close to the median of 532 across 25 observational studies indexed under Schistosomiasis.

Browse Schistosomiasis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over 18 years-old with a diagnosis of schistosomiasis in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18, positive schistosomiasis immunoblot and / or positive microscopy examination for schistosomiasis eggs

Exclusion criteria

Exclusion Criteria:

    • patients under guardianship
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
532 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Describe the management of patients with chronic schistosomiasis in France, in terms of diagnosis, assessment, management and follow-up.

    Draft of new clarified recommendations on the overall management of this pathology

    Time frame: 12 months

07

Study locations

1 site
  • hospital BICETRE
    Le Kremlin-Bicêtre, France
08

References and documents

Individual participant data

Plan to share: No — No sharing

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04810741
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Dec 21, 2021
Primary completion
May 18, 2022
Completion
May 18, 2022
Last update
Jan 13, 2023

Study contacts

Stephane Jareguiberry, Professor
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion